首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 再生醫學細胞療法基因療法

市場調查報告書

商品編碼

1935190

中樞神經系統疾病基因和細胞療法市場：按治療方法、適應症和地區分類

Gene and Cell Therapies Targeting CNS Disorders Market, By Therapy Type, By Indication, By Geography

出版日期: 2026年01月12日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026 年，中樞神經系統疾病的基因和細胞療法市場規模預計為 79 億美元，預計到 2033 年將達到 240 億美元，2026 年至 2033 年的年複合成長率（CAGR）為 16.5%。

報告內容		報告詳情
基準年：	2025	2026年市場規模：	79億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
預測期（2026-2033年）複合年成長率：	16.50%	2033 年的預測值：	240億美元

目前，市場正經歷變革時期，分子生物學、遺傳學和再生醫學領域的突破性進展正在重新定義中樞神經系統疾病的治療模式。傳統上，由於大腦和脊髓結構的複雜性以及血腦障壁的存在，中樞神經系統疾病的治療主要以症狀治療為主。然而，基因和細胞療法克服了這些挑戰，實現了標靶治療、緩解疾病治療，甚至根治性治療。

針對中樞神經系統疾病的基因和細胞療法涵蓋了多種複雜的治療方法，包括基於病毒載體的基因替代療法、基因靜默和編輯技術（包括 CRISPR）、誘導多能幹細胞 (iPS 細胞) 衍生的神經前驅細胞以及各種幹細胞移植方法。這些治療方法旨在糾正基因缺陷、恢復神經元功能、替換受損細胞或在分子層面調節疾病路徑。神經遺傳學和神經生物學的進步促進並加速了該領域的創新，使中樞神經系統疾病成為一個日益引人注目且前景廣闊的治療領域。

帕金森氏症、阿茲海默症、亨丁頓舞蹈症、肌萎縮側索硬化症和多發性硬化症等神經退化性疾病疾病發病率的不斷上升是推動市場成長的關鍵因素。隨著人口老化加劇、診斷技術進步以及公眾健康意識的提高，這些疾病的發生率持續上升。

市場動態

由於神經退化性疾病的日益增加以及對緩解疾病治療方法的迫切需求，中樞神經系統疾病的基因和細胞療法市場正受到廣泛關注。帕金森氏症和阿茲海默症疾病在全球範圍內的發病率持續上升，給全球醫療保健系統帶來了沉重負擔。這推動了人們對能夠解決疾病根本原因而非僅僅緩解症狀的最先進治療方案的需求。

技術進步是推動市場未來發展的另一個主要因素，預計將產生重大影響。病毒載體技術（從腺結合病毒（AAV）到慢病毒載體）的進步提高了載體遞送至中樞神經系統（CNS）的效率和安全性。同樣，幹細胞研究領域的進步也促成了功能明確且可規模化生產的幹細胞的開發，這些幹細胞可用於中樞神經系統移植。

監管環境也正在朝向有利於市場擴張的方向轉變。美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構正日益提供加速核准流程、孤兒藥認定以及專門針對先進療法藥品（ATMP）的監管指導。這些舉措縮短了研發週期，為生產商提供了更清晰的指導，從而刺激了中樞神經系統基因和細胞治療領域的投資和創新。

此外，將人工智慧 (AI) 和數位健康技術應用於中樞神經系統 (CNS) 治療藥物的研發，正在提高臨床試驗的效率和成功率。機器學習患者分層、數位生物標記和即時疾病監測解決方案，使得試驗、終點測量和上市後監測能夠更加精準。這是一項至關重要的進展，因為中樞神經系統疾病歷來因其複雜性和進展緩慢而難以進行臨床評估。

本次調查的主要特點

本報告詳細分析了中樞神經系統疾病的基因和細胞療法市場，以 2025 年為基準年，給出了預測期（2026-2033 年）的市場規模（十億美元）和複合年成長率（%）。
它重點介紹了各個細分市場的潛在商機，包括治療方法類型、適應症和地區，並解釋了該市場具有吸引力的投資提案矩陣。
該研究深入分析了市場促進因素、限制因素、機會、技術突破、監管發展、高級臨床試驗、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本報告根據以下參數對中樞神經系統疾病基因和細胞治療市場的主要企業進行了分析：公司概況、治療產品線、技術平台、關鍵發展和策略舉措。
本報告的研究結果將使負責人和經營團隊能夠就未來的產品發布、治療方法進步、市場擴張和行銷策略做出明智的決策。
這份《中樞神經系統疾病基因和細胞療法市場》報告的目標受眾是業內各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析中樞神經系統疾病基因和細胞治療市場所使用的各種策略矩陣輕鬆做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第7章競爭情勢

熱圖分析
市佔率分析（3x3矩陣）
公司簡介
- Novartis
- BrainStorm Cell Therapeutics
- Corestem
- Q Therapeutics
- Helixmith
- Rapa Therapeutics
- Neuroplast
- StemCyte
- Ferrer Internacional
- Neuralstem
- Stemedica Cell Technologies
- Libella Gene Therapeutics
- Sangamo Therapeutics
- Hoffmann-La Roche
- LSio Gene Therapies
- Eli Lilly and Company
- NeuroGeneration
- Brain Neurotherapy Bio（AskBio）
- UniQure Biopharma

第8章分析師建議

機會
分析師觀點
Coherent Opportunity Map

第9章各節

參考
調查方法

簡介目錄

Product Code: CMI4705

Gene And Cell Therapies Targeting Cns Disorders Market is estimated to be valued at USD 7.9 Bn in 2026 and is expected to reach USD 24.0 Bn by 2033, growing at a compound annual growth rate (CAGR) of 16.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7.9 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	16.50%	2033 Value Projection:	USD 24.0 Bn

The market is at a transformational phase now, wherein the breakthroughs in molecular biology, genetics, and regenerative medicine are rewriting the treatment paradigms for CNS disorders. Traditionally, CNS diseases were managed by symptomatic treatments due to the intricacies in the brain and spinal cord along with the presence of the blood-brain barrier. Gene and cell therapies, however, can now circumvent such difficulties and allow targeted, disease-modifying, and potentially curative interventions.

Gene and cell therapies targeting CNS disorders cover a wide range of sophisticated therapeutic modalities, including viral vector-based gene replacement; gene silencing and editing technologies, including CRISPR; induced pluripotent stem cell-derived neural progenitors; and a variety of stem cell transplantation approaches. These therapies aim at correcting genetic defects, restoring neuronal function, replacing damaged cells, or modulating disease pathways at a molecular level. Neurogenetics and neurobiology have ignited and accelerated innovation in this field to date, making CNS disorders a viable and increasingly attractive therapeutic area.

The increasing incidence of neurodegenerative and neurological disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis is a significant factor contributing to the growth of the market. With the rising geriatric population, advancements in diagnostic technologies, and greater awareness, the incidence of diseases is on a rise.

Market Dynamics

The market for gene and cell therapies targeting CNS disorders has been gaining significant traction due to the increasing prevalence of neurodegenerative diseases and the urgent unmet need for disease-modifying treatments. Such diseases as Parkinson's disease and Alzheimer's continue to increase in incidence throughout the world, placing a significant burden on the global health care system. This, in turn, increases the need for cutting-edge treatment solutions targeting the root cause of diseases instead of just relieving symptoms.

Technological advancements, another major driving factor which is anticipated to have a significant future impact on the development of the market is technological advancements. Advances in the technology area for viral vectors, ranging from adeno-associated virus (AAV) to lentiviral vectors, have resulted in enhanced delivery efficacy and safety associated with the vectors to the CNS. Similarly, advances in the area of stem cell research have resulted in the development of stem cells that are scalable and well-characterized from a functional perspective for transplantation purposes in the CNS.

The regulatory landscape is also evolving in favor of market expansion. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly offering accelerated approval pathways, orphan drug designations, and regulatory guidance specifically tailored to advanced therapy medicinal products (ATMPs). These initiatives reduce development timelines and provide greater clarity for manufacturers, thereby encouraging investment and innovation in the CNS gene and cell therapy space.

Moreover, the incorporation of artificial intelligence and digital health technologies into CNS therapeutic development is improving the efficiency and rates of clinical trials. The use of machine learning approaches to stratify patients, digital biomarkers, and real-time disease monitoring solutions are allowing for more focused trials, measurement of endpoints, and post-market surveillance. This is significant, as it is in the realm of CNS disorders, where the complexity and slowing rate of progression have traditionally clouded clinical assessment.

Key Features of the Study

This report provides in-depth analysis of the Gene and Cell Therapies Targeting CNS Disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.
It elucidates potential revenue opportunities across different segments such as therapy type, indication, and geography, and explains attractive investment proposition matrices for this market.
This study provides key insights about market drivers, restraints, opportunities, technological breakthroughs, regulatory developments, advanced-stage clinical trials, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the gene and cell therapies targeting CNS disorders market based on the following parameters - company overview, therapeutic pipeline, technology platforms, key developments, and strategic initiatives.
Key companies covered as part of this study include Novartis, BrainStorm Cell Therapeutics, Corestem, Q Therapeutics, Helixmith, Rapa Therapeutics, Neuroplast, StemCyte, Ferrer Internacional, Neuralstem, Stemedica Cell Technologies, Libella Gene Therapeutics, Sangamo Therapeutics, Hoffmann-La Roche, LSio Gene Therapies, Eli Lilly and Company, NeuroGeneration, Brain Neurotherapy Bio (AskBio), and uniQure Biopharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Gene and Cell Therapies Targeting CNS Disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Gene and Cell Therapies Targeting CNS Disorders Market

Market Segmentation

Therapy Type Insights (Revenue, USD Bn, 2026 - 2033)
- Gene Therapy
- Cell Therapy
Indication Insights (Revenue, USD Bn, 2026 - 2033)
- Alzheimer's Disease (AD)
- Huntington's Disease (HD)
- Parkinson's Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease
- Multiple Sclerosis (MS)
- Adrenoleukodystrophy & Metachromatic Leukodystrophy
- Neuropathies
- Batten Disease (BD)
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis
- BrainStorm Cell Therapeutics
- Corestem
- Q Therapeutics
- Helixmith
- Rapa Therapeutics
- Neuroplast
- StemCyte
- Ferrer Internacional
- Neuralstem
- Stemedica Cell Technologies
- Libella Gene Therapeutics
- Sangamo Therapeutics
- Hoffmann-La Roche
- LSio Gene Therapies
- Eli Lilly and Company
- NeuroGeneration
- Brain Neurotherapy Bio (AskBio)
- UniQure Biopharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Indication
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend

4. Global Gene And Cell Therapies Targeting CNS Disorders Market, By Therapy Type, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Gene Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cell Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Gene And Cell Therapies Targeting CNS Disorders Market, By Indication, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Alzheimer's Disease (AD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Huntington's Disease (HD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Parkinson's Disease (PD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Multiple Sclerosis (MS)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adrenoleukodystrophy & Metachromatic Leukodystrophy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Neuropathies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Batten Disease (BD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Gene And Cell Therapies Targeting CNS Disorders Market, By Region, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- Novartis
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- BrainStorm Cell Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Corestem
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Q Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Helixmith
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Rapa Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Neuroplast
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- StemCyte
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Ferrer Internacional
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Neuralstem
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Stemedica Cell Technologies
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Libella Gene Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Sangamo Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Hoffmann-La Roche
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- LSio Gene Therapies
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Eli Lilly and Company
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- NeuroGeneration
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Brain Neurotherapy Bio (AskBio)
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- UniQure Biopharma
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates